H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of Dyadic International (DYAI) with a Buy rating and $3 price target The company produces recombinant proteins based on proprietary fungus-based platforms, the analyst tells investors in a research note. The firm is “encouraged” by Dyadic’s efforts to expand its platform into further non-pharmaceutical applications and views them as upside to estimates.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYAI:
- Dyadic International Achieves Milestone Payments and Compliance
- Dyadic International announces achievement of milestone payments
- Dyadic International Amends Security Agreement with CEO Trust
- Craig-Hallum bullish on Dyadic International, initiates with a Buy
- Dyadic International initiated with a Buy at Craig-Hallum